NASDAQ:HRMY
Harmony Biosciences Holdings Inc (HRMY-Q)
Financials
Technical Analysis
Buy, Sell or Hold?
Related posts
Nervous markets await Nvidia
Premium contentHRMY is a bio-pharma company that has developed cannabis based CBD gels in the US. It is making potentially great strides on developing a treatment for narcolepsy. It trades at 14x earnings, 2.8x book and supports a 24% ROE. Cash reserves are growing, while debt is retired. We recommend setting a stop-loss at $30, looking to achieve $49 -- upside potential of 37%. Yield 0%
(Analysts’ price target is $49.70)- «
- ‹
- 1
- ›
- »
Harmony Biosciences Holdings Inc(HRMY-Q) Rating
Ranking : 1 out of 5
Bullish - Buy Signals / Votes : 0
Neutral - Hold Signals / Votes : 0
Bearish - Sell Signals / Votes : 0
Total Signals / Votes : 0
Harmony Biosciences Holdings Inc(HRMY-Q) Frequently Asked Questions
What is Harmony Biosciences Holdings Inc stock symbol?
Harmony Biosciences Holdings Inc is a American stock, trading under the symbol HRMY-Q on the NASDAQ (HRMY). It is usually referred to as NASDAQ:HRMY or HRMY-Q
Is Harmony Biosciences Holdings Inc a buy or a sell?
In the last year, there was no coverage of Harmony Biosciences Holdings Inc published on Stockchase.
Is Harmony Biosciences Holdings Inc a good investment or a top pick?
Harmony Biosciences Holdings Inc was recommended as a Top Pick by on . Read the latest stock experts ratings for Harmony Biosciences Holdings Inc.
Why is Harmony Biosciences Holdings Inc stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
Is Harmony Biosciences Holdings Inc worth watching?
0 stock analysts on Stockchase covered Harmony Biosciences Holdings Inc In the last year. It is a trending stock that is worth watching.
What is Harmony Biosciences Holdings Inc stock price?
On 2025-08-29, Harmony Biosciences Holdings Inc (HRMY-Q) stock closed at a price of $36.89.
We reiterate this commercial stage pharma company focusing on neurological treatment as a TOP PICK. It has a long runway of projects in the development pipeline and its histamine focused foundation treatment continues to create positive cash flow and growing cash reserves. We recommend trailing up the stop (from $30) to $33, looking to achieve $50 -- upside potential of 33%. Yield 0%
(Analysts’ price target is $50.55)